GB1574959A - Benzofuran derivatives - Google Patents
Benzofuran derivatives Download PDFInfo
- Publication number
- GB1574959A GB1574959A GB14242/77A GB1424277A GB1574959A GB 1574959 A GB1574959 A GB 1574959A GB 14242/77 A GB14242/77 A GB 14242/77A GB 1424277 A GB1424277 A GB 1424277A GB 1574959 A GB1574959 A GB 1574959A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- dihydro
- methoxy
- grams
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Description
(54) BENZOFURAN DERIVATIVES
(71) We, GRUPPO LEPETIT, S.p.A., an Italian Body Corporate, Via
Roberto Lepetit 8, Milan, Italy, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- This invention relates to novel 2,4,6-trisubstituted-2,3-dihydrobenzofurans.
Some 2,4,6-trisubstituted-benzofurans are known; see, for instance, A. Wahhab, J.
Prakt. Chem. 314, 213, 1972. Other benzofurans variously substituted at one or more of the possible positions are described in Bull. Soc. Chim. Fr., page 915, 1967,
J. Org. Chem., 28, 398, 1963 and J. Org. Chem., 30, 1246, 1965.
According to the present invention, there are provided compounds of the formula
wherein R is hydrogen or methyl; one of R1 and R2 is hydroxy, C1~4alkoxy or C24alkanoyloxy and the other is selected from cyano, carboxy, carbo(C,~4)alkoxy, carbamoyl and a -NR3R4 group, wherein R3 and R4 independently represent hydrogen, (C14)alkyl, (C24)alkanoyl, carbo(C14)alkoxy, carbobenzyloxy, carbamoyl, mono- and di-(C,~4)alkylamino-(C1~4)alkyl benzenesulfonyl toluenesulfonyl, (C1~4)alkylsulfonyl or phenacylsulfonyl; and salts therewith of pharmaceutically acceptable acids. The compounds possess antinflammatory, analgesic and antipyretic utility. The expression "(C1~4)alkyl" as used herein identifies alkyl radicals selected from methyl, ethyl, propyl, isopropyl, butyl, secbutyl and tert-butyl; the term "(C1~4)alkoxy" designates alkoxy groups selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy and tert-butoxy; the term "(C24)alkanoyloxy" refers to alkanoyloxy groups selected from acetyloxy, propionyloxy or butyryloxy; the term "lower (C24)alkanoyl; identifies alkanoyl radicals selected from acetyl, propionyl and butirryl. A preferred group of compounds comprises those compounds of formula I wherein R stands for hydrogen or methyl, one of R1 and R2 represents hydroxy, (C1~4)alkoxy as above defined or (C24)aliphatic alkanoyloxy as above defined, and the other one represents the group -NR3R4 wherein R3 and R4 each independently represents hydrogen or a (C1~4)alkyl group as above defined; and salts therewith of pharmaceutically acceptable acids. A most preferred group of compounds comprises those compounds of formula I wherein R is a hydrogen atom, one of R1 and R2 is a (C1~4)alkoxy group as above defined and the other one is the group -NR3R4 wherein R3 and R4 each independently represent hydrogen or (C14)alkyl as above defined; and salts therewith of pharmaceutically acceptable acids.
Acids especially suitable for the formation of therapeutically useful salts are both organic and inorganic. Such acids are, for example, aliphatic or aromatic carboxylic acids, e.g. formic, acetic, succinic, oxalic, malic, tartaric, citric, ascorbic, benzoic and salicylic acid and mineral acids, e.g. hydrochloric, hydrobromic, sulfuric, phosphoric or perchloric acid. The compounds of this invention are prepared according to methods which involve, as the first step, formation of the basic 2,3-dihydrobenzofuran skeleton through cyclization of a compound of formula II
wherein R is defined as above. For the purposes of this invention, the radical -CH2-CH=CH-R must be located either at the 2- or the 4-position. Thus, when R represents hydrogen, the compound of formula II is an o-allylphenol derivative; when R is methyl, the compound of formula II is an o-crotylphenol derivative.
Depending on the position of the allyl or crotyl group on the benzene ring,
cyclization to 2,3-dihydrobenzofurans is achieved through thermal or acid induced
ring closure as summarized in the following schemes:
Scheme A
Scheme B
In practice, cyclization of 2-allyl- or 2-crotyl-3-hydroxy-5-methoxybenzoic acid methyl esters according to Scheme A is performed by heating the starting material in an inert atmosphere, e.g. nitrogen or carbon dioxide atmosphere, to a temperature ranging from about 200"C to about 280"C for about 2--4 hours. The cyclized compound is then recovered according to the usual procedures which comprise dissolution of the cooled reaction mass in an aqueous alkaline solution, extraction with a water-immixable organic solvent, evaporation of the organic phase and purification of the product by vacuum distillation or column chromatography. Alternatively, this reaction can be carried out in a neutral or basic high-boiling organic solvent; heating the obtained reaction mixture to the reflux temperature for 2-6 hours.
At the end ofthis time the solvent is evaporated and the cyclization product is recovered as described above.
According to scheme B above the acid-induced cyclization of 4-allyl- or 4crotyl-3-hydroxy-5-methoxybenzoic acid methyl esters is carried out by dissolving the starting material in acetic acid and subsequently adding hydrobromic acid.
The reaction may be performed at room temperature, however it is generally preferred to heat or even reflux the obtained reaction mixture in order to speed up the reaction which can be completed in l----l hours. Separation and purification of the obtained 2,3-dihydrobenzofurans is achieved according to the usual procedures, bearing in mind that the acidic reaction conditions afford the hydrolysis of the carbomethoxy group. It has also been found that, when the reaction time is prolonged up to 7-10 hours, also the hydrolysis of the methoxy group to hydroxy takes place.
The starting materials of formula II can be easily prepared by Claisen rearrangement of allyl phenyl ethers of formula III
wherein R is hydrogen or methyl, performed as described by Tarbell in Organic
Reactions, vol. II, New York, 1944, i.e. by heating the allylphenyl ether in the absence of any solvent to a temperature comprises between 180 and 2200C, or refluxing a solution of a compound of formula III in a basic or neutral high-boiling organic solvent.
Suitable solvents which may be employed comprise N,N-dimethylaniline, N,Ndiethylaniline, paraffin oil, tetralin and kerosine. The rearrangement is preferably carried out in an inert atmosphere. Recovery of the obtained isomers is achieved according to the usual procedures taking advantage of the different solubilities of the corresponding carboxylic acids, obtained by alkaline hydrolysis, in aqueous solutions.
Alternatively, the two isomers can be precipitated as a mixture and separated by column chromatography. Usual esterification procedures afford the desired products of formula II.
Pursuant to the procedures outlined in schemes A and B, compounds of formula I are obtained wherein R stands for hydrogen or methyl, one of R1 and R2 is a methoxy radical and the other is a carboxy or carbomethoxy group.
When other compounds of formula I are desired, then the corresponding groups have to be introduced by obvious chemical modifications, which are entirely familiar to an average technician. Thus, the alkaline hydrolysis of the 4positioned carbomethoxy substituent leads to the corresponding carboxy group which in turn, as well as the carboxy group at the 6-position formed in the acidinduced cyclization, may be reacted with a (C, 4)alkanol in the presence of a strong acidic medium to yield the desired 4- or 6-c rbo(C,~4)alkoxy derivatives.
The carboxy group at the 4- or 6-position may undergo other chemical modifications. For convenience purposes, it is first transformed into the more reactive -COhal group, wherein hal stands for a halogen atom, preferably chloro or bromo, which may in turn be converted into the corresponding -CON3 group by reaction with NaN3.
Alternatively, the --COhal group is transformed by ammonolysis into the corresponding amide which may be dehydrated, thus giving compounds of formula
I wherein R, or R2 is cyano.
The benzofurans bearing the -CON3 group at the 4- or 6-position, prepared as described above, are intermediates for preparing other compounds falling within the scope of the general formula.
Thus, the thermal decomposition of the -CON3 group affords compounds of formula I wherein R, or R2 represent amino i.e., the group -NR3R4 in which R3 and R4 are hydrogen whereas, if the decomposition takes place in the presence of a (C,~4)alkanol or benzyl alcohol, compounds of formula I are obtained wherein R1 and R2 represent a carbo(C,~4)alkoxyamino or carbobenzyloxyamino radical. From these compounds, by means of a simple reductive step, the compounds where R, or
R2 represent methylamino are easily prepared. Among the reducing agents, lithium aluminum hydride is the most preferred one.
Also the substituents R3 and R4 different from hydrogen are introduced by means of known procedures by reacting the corresponding 4- or 6-unsubstituted amino derivatives with appropriate reactants.
Thus, for instance, reaction with an alkylating agent, such as (C,~4)alkyl halides or (C,~4)alkyl sulfates, affords compounds wherein R3 or R4 or both are (C,~4)alkyl groups. Compounds wherein R3 or/and R4 represent a (C24)alkanoyl radical are obtained by reacting the corresponding compounds wherein R3 or/and
R4 are hydrogen with halides or anhydrides of (C24)aliphatic acids.
Carbo(C,~4)alkoxy and carbobenzyloxy amino groups are obtained by reaction with corresponding (C1~4)alkyl and benzyl carbonates.
They may in turn be converted into the 4- or 6-methylamino derivatives as outlined above. The benzenesulfonyl, toluenesulfonyl, (C,~4)alkylsulfonyl and phenacylsulfonyl groups are conveniently introduced by reaction with benzenesulfonyl-, toluenesulfonyl-, (C,~4)alkylsulfonyl- and phenacylsulfonyl halides respectively, whereas the carbamoyl group may be introduced by reacting the unsubstituted amino derivative with an alkali isocyanate in an acidic medium.
A useful route to the compounds wherein one of R, and R2 is a (C24)alkylamino group is represented by the reduction of the (C24)acyl substituents of the amino group.
Finally, also the corresponding 4- or 6-positioned methoxy group may be transformed by known chemical reactions into another group falling within the meanings given for said substituent: demethylation may be done by refluxing the compound with HBr/AcOH mixtures or alternatively refluxing a CS2 or nitrobenzene solution of the compound with anhydrous AlCl3 and decomposing the obtained aluminum complex with water. Reaction of the thus obtained hydroxy derivative with (C24)alkyl sulfates in strongly alkaline medium affords the corresponding (C24)alkoxy derivatives, whereas the 4- or 6-positioned (C2~4)alkanoyloxy group may be obtained through reaction with a suitably selected (C24)aliphatic acyl halide or anhydride in acidic conditions.
It is intended that alternative methods which can suitably be employed for transforming a pre-existing radical into another falling within the giveri meanings, although not specifically disclosed, are to be considered within the scope of the present invention.
As stated above the compounds of the present invention possess antiinflammatory, analgesic and antipyretic utility. They also possess a low toxicity, since the LD50 values are never lower than 1000 mg/kg orally in mice and higher than 2000 mg/kg orally in rats. The toxicities were determined according to
Lichtfield and Wilcoxon, Journ. Parm. Expt. Ther., 96, 99, 1949.
The anti-inflammatory activity was ascertained by means of several testingmethods; in one, the ability of the compounds of the invention to reduce the edema induced in the rat paw by injection of carrageenin was evaluated and the test was performed according to the methodology described by C. A. Winter et al. in Proc.
Soc. Exptl. Biol. Med. 111, 544, (1962). In another it was investigated the reduction by the test compounds of the weight bf the granuloma formed on a cotton pellet implanted subcutaneously in a rat, following the method described by Meier et al.
In Experientia 6, 469, (1950).
Representative experiments have shown that the compounds of Example 11, namely 2,3-dihydro-6-methoxy-N,2-dimethyl-4-benzofuranamine causes a reduction of the carrageenin induced edema of around 70 percent over the controls even when it is administered at an absolutely safe dosage i.e., around 1/5 of its
LD50. In the granuloma cotton pellet test the same compound at the same dosage reduces the weight of the granuloma of more than 40 percent again over the controls.
However, the most important pharmacological aspect of the compounds of the present invention is that they are effective also in the adjuvant induced arthritis test in rats. This test is absolutely meaningful in that adjutant arthritis is one of the best pharmacological parameters with which a pharmacologist investigate compounds as to their possible anti-inflammatory activity, owing to the parallelism of effects existing between it and some articulation diseases observed in humans (see
Pearson, C.M., Arthritis and allied conditions, page 119, Lea and Febiger Publ., 1967 and Pearson C.M., J. Chronic Diseases, 16, 863, 1963).
The adjuvant induced arthritis test was performed as described by B.B.
Newbould in Brit. Jour. Pharmacol., 21, 127, (1963). The measure of effectiveness of'the compounds in this test is given by their ability in reducing the volume of the hind paws of the laboratory animals. In still another representative experiment, the compound of Example 11 proved to be significantly more active in the adjutant induced arthritis test than acetylsalicylic acid, which is one of the most effective
and widely employed antirheumatic drug. The obtained results, which are
summarized in the following table, were obtained by testing the compounds at a
dosage corresponding to 1/5 of their LD50.
TABLE % reduction of the LDso mg/kg Dose mg/kg volume of the hind paws
Compound rats p.o. rats p.o. over the controls 2,3-dihydro-6-methoxy
N,2-dimethyl-4
benzofuranamine 2800 200 36 acetylsalicylic acid 1400 200 25
These favorable characteristics are coupled also with interesting analgesic and
antipyretic properties which were investigated according to the methods described
by Randall et al. in Arch. Int. Pharmacodyn. 111, 409, (1957) and by Builler et al. in
J. Pharm. Pharmacol. 9, 128, (1957), respectively. It is finally to be noted that the
new 2,3-dihydro-benzofuran derivatives which are the object of the present
invention display a very low ulcerogenic activity which is several times lesser than
the one observed with other known and therapeutically used anti-inflammatory
substances. The ulcerogenic action was determined according to Thuillier et al.
Chim. Ther. 3, 51, (1968).
The following Examples illustrate the process of the invention and describe in
detail some compounds of general formula I without limiting the scope of the
invention.
Example 1 2,3-dihydro-6-methoxy-2-methyl-4-benzofurancarboxylic acid methyl ester
2-allyl-3-hydroxy-5-methoxybenzoic acid methyl ester is heated under
nitrogen atmosphere to 2600C for about 3 hours. Upon cooling, the reaction mass
is dissolved in a small amount of 20%KOH and the aqueous alkaline solution is then
extracted with ethyl ether. The organic phase is evaporated and the crude residue
affords the title compound in 450/, yield. B.p./0.3 mmHg 136--380C.
Example 2 2, 3-dihydro-4-methoxy-2-methyl-6-benzofurancarboxylic acid
1 gram of 4-allyl-3-hydroxy-5-methoxybenzoic acid methyl ester in 5 cc of
glacial acetic acid and 1.5 cc of 48VnHB R is refluxed for 3 hours. After this time the
mixture is concentrated to dryness and the crude residue is dissolved in an aqueous
alkali solution. 0.3 grams of dimethyl sulfate are added to the resulting solution
which is refluxed for two additional hours. The compound of the title which
precipitates upon acidification of the cooled reaction mixture is recrystallized from
ethyl ether-petroleum ether. Yield 60%. M.p. 180--182"C.
Example 3 2,3-dihydro-4-hydroxy-2-methyl-6-benzofurancarboxylic acid
A mixture of 30 grams of 4-allyl-3-hydroxy-5-methoxybenzoic acid, 150 cc of
glacial acetic acid and 45 cc of 48 /"HBr is heated to the reflux temperature for 8
hours. After this time the reaction mixture is concentrated to dryness and the
obtained residue, ground with water and filtered is crystallized from ethyl ether
petroleum ether. The product is obtained in a yield of 19.9 grams (71 percent of
theoretical) and has a melting point of 181--184"C.
Example 4 2,3-dihydro-6-hydroxy-2-methyl-4-benzofurancarboxylic acid
-To a solution of 35 grams of 2,3-dihydro-6-methoxy-2-methyl-4
benzofurancarboxylic acid methyl ester, prepared in Example l, in 160 cm of acetic
acid, 60 cc of 48%HBr are added and the resulting mixture is refluxed for 16 hours.
After this time the reaction mixture is concentrated to dryness and the residue is
dissolved in concentrated NaOH. The obtained solution, heated in a hot water-bath
for 2 hours, is then cooled, acidified with concentrated HCI and extracted with
ether. Evaporation of the ether extract affords a crude residue which is purified by
column chromatography using a mixture CHCI3-MeOH as the eluting system
wherein the percentage of MeOH is gradually increased. The compound of the
title, recovered from the last fractions (CHCl3+307 MeOH), is then crystallized from ethyl ether-petroleum ether. Yield 14.2 g (47 percent of theoretical). M.p.
225--27"C.
Example 5 6-ethoxy-2,3-dihydro-2-methyl-4-benzofurancarboxylic acid
6.9 grams of the compound prepared in the preceding example are dissolved in 25 cc of 22% NaOH and the resulting solution maintained at 300C during the dropwise addition of 9 cc of diethyl sulfate, is then refluxed for 2 hours. After adding 2 cc of concentrated NaOH, heating is continued for two additional hours.
At the end of this time the mixture is cooled, acidified with concentrated HCI and filtered.
The solid recovered on filter is dissolved in ethyl ether and the obtained solution, dried over Na2SO4, is then concentrated to a small volume. The solid which precipitates upon addition of petroleum ether is recrystallized from ethyl ether yielding 5.9 grams (75% of theoretical) of 6-ethoxy-2,3-dihydro-2-methyl-4- benzofurancarboxylic acid which melts at 155--157C.
Example 6 (6-ethoxy-2,3-dihydro-2-methyl-4-benzofuranyl)carbamic acid ethyl ester
a) A solution consisting of 5.7 grams of 6-ethoxy-2,3-dihydro-2-methyl-4benzofurancarboxylic acid, prepared in example 5, 3.7 cc of SOCI2, a few drops of
N,N-dimethylformamide and 60 cc of anhydrous benzene, is gently refluxed for 4 hours. At the end of this time the reaction mixture is concentrated to dryness and the obtained residue, dissolved in 65 cc of acetone,is cooled to 50C while a solution of 2.8 grams of sodium azide in 8 cc of water is gradually added under stirring.
Stirring, at the same temperature, is prolonged for an additional hour then the reaction mixture is poured into ice-water and extracted with ether. Evaporation of the organic phase affords an oily residue which is the azide of the starting carboxylic acid.
b) This oily residue, dissolved in 60 cc of anhydrous xylene, is gradually heated up to 1200C and maintained at this temperature for 30 minutes. After this time 10 cc of EtOH are added drop by drop to the reaction mixture which is then refluxed for 3 hours.
The residue obtained by evaporating the solvent is finally crystallized from ethyl ether yielding 5.3 grams (93 percent of theoretical) of the compound of the title. M.p. 640C.
Example 7 6-ethoxy-2,3-dihydro-N,2-dimethyl-4-benzofuranamine hydrochloride
A solution of 4.1 grams of the compound prepared in the preceding example in 30 cc of anhydrous benzene is gradually added to a suspension of LiAIH4 (1 gram) in anhydrous ethyl ether (35 cc). The obtained reaction mixture, refluxed for 6 hours, is then cooled and the aluminum complex is decomposed by addition of 3 cc of water. After stirring at room temperature for 30 minutes the inorganic salts are discarded by filtration, the filtrate is evaporated and HCI is bubbled in a solution of the obtained residue in ethyl ether. The precipitate which forms is recovered on filter and recrystallized from ethyl alcohol-ethyl ether yielding 3 grams (80 percent of theoretical) of the compound of the title which melts at 173--1750C.
Example 8 2,3-dihydro-6-methoxy-2-methyl-4-benzofurancarboxylic acid
To a stirred mixture of 158 grams of 2,3-dihydro-6-methoxy-2-methyl-4benzofurancarboxylic acid methyl ester and 88.5 grams of flake sodium hydroxide in 320 cc of water, ethanol is gradually added until a clear solution is obtained.
The reaction mixture is allowed to stand at room temperature for about five hours then the solvent is evaporated under reduced pressure and the obtained residue, taken up with water and acidified with diluted HCI, is extracted with ether.
By concentrating to dryness the organic phase and crystallizing the residue from ethyl ether on addition of petroleum ether, 106 grams (71.6 percent of theoretical) of the compound of the title are obtained. M.p. 153--1550C.
Example 9
2,3-dihydro-6-methoxy-2-methyl-4-benzofuranamine
70 cc of SOCI2 are dripped at room temperature into a stirred solution of 106.8 grams of 2,3-dihydro-6-methoxy-2-methyl-4-benzofurancarboxylic acid in 840 cc of anhydrous benzene. When the addition is terminated the reaction mixture is heated to 800C for 5 hours and then concentrated to dryness. The thus obtained residue, consisting of the acyl chloride of the starting acid, is purified by crystallization from ethyl ether-petroleum ether and dissolved in 1370 cc of anhydrous acetone. To the resulting solution cooled under stirring to +50C, 61.6 grams of NaN3 dissolved in 180 cc of water are gradually added. The same temperature is maintained for an additional hour then the reaction mixture is poured into 4600 cc of distilled cold water. Extraction with ethyl ether and evaporation of the organic phase affords the crude azide of the starting carboxylic acid which is purified by crystallization from ethyl ether.
A solution of this intermediate in 100 cc of ethyl ether is gradually added under stirring to 600 cc of ethylene glycol heated in an oil-bath to 850 C. When the addition is terminated, the temperature is increased to 2200C for 5 minutes then the reaction mixture is alkalized by means of an ethylene glycol solution of 98 grams of flake KOH and refluxed for 20 minutes. After cooling, the reaction mixture is poured into 1200 cc of distilled icy water, stirred for 10 minutes, acidified with concentrated HCI and, after 15 minutes, made basic again with concentrated
NaOH. By extracting with ethyl ether, evaporating this organic extract and crystallizing the resulting residue from petroleum ether, 81 grams of the compound of the title are obtained. M.p. 59--610C. Overall yield, calculated on the starting carboxylic acid, 88.60/,.
Example 10 (2,3-dihydro-6-methoxy-2-methyl-4-benzofuranyl)carbamic acid ethyl ester
55.75 grams of ethyl chlorocarbonate in 100 cc of anhydrous benzene are gradually added at 50C to a stirred solution of 81 grams of 2,3-dihydro-6-methoxy2-methyl-4-benzofuranamine and 46 cc of triethylamine in 700 cc of anhydrous benzene. At the end of the addition, the reaction mixture is slightly warmed and stirring is continued, at room temperature, for 3 hours.
After this time the reaction mixture is refluxed for two hours, then cooled, washed with water, dried over Na2SO4 and concentrated to dryness yielding 95.81 grams (83.5 percent of theoretical) of the compound of the title B.p./0.4 mmHg 1720C.
Example 11 2,3-dihydro-6-methoxy-N,2-dimethyl-4-benzofuranamine 95.81 grams of (2,3-dihydro-6-methoxy-2-methyl-4-benzofuranyl)carbamic acid ethyl ester prepared in the foregoing example, are dissolved in 385 cc of anhydrous ethyl ether and the resulting solution is dripped into a stirred suspension of 21.01 grams of LiAIH4 in 600 cc of anhydrous ethyl ether cooled to OOC, then the obtained reaction mixture is refluxed for 5 hours. After cooling, 63 cc of cold distilled water are added to the reaction mixture and the inorganic salts which precipitate are discarded by filtration. The filtrate, dried over Na2SO4 is evaporated yielding an oily residue which purified by under vacuum distillation affords 34 grams of the compound of the title B.p./0.3 mmHg 1370C. This compound, which easily solidifies, melts at 530C (from ether-petroleum ether). The corresponding hydrochloride melts at 1470C.
Example 12 N-(2,3-dihydro-6-methoxy-2-methyl-4-benzofuranyl)propanamide The compound of the title is prepared according to the procedure described in
Example 10 by reacting the starting 2,3-dihydro-6-methoxy-2-methyl-4benzofuranamine with propionyl chloride instead of ethylchlorocarbonate.
M.p. 101---020C (from ethyl ether). Yield 44 grams (75 percent of theoretical).
Example 13 2,3-dihydro-6-methoxy-2-methyl-N-propyl-4-benzofuranamine A solution of 3.2 grams of N-(23-dihydro-6-methoxy-2-methyl-4- benzofuranyl)propanamide, prepared in the foregoing example, in 30 cc of anhydrous benzene is gradually added into a suspension of 1.1 grams of LiAlH4 in 30 cc of anhydrous ethyl ether at OOC and the resulting reaction mixture is heated to the reflux temperature for 6 hours. At the end of this time the temperature is decreased to OOC and the aluminum complex is decomposed by addition of 3.3 cc of water. After 30 minutes of stirring at room temperature, the inorganic salts are discarded by filtration and the filtrate, dried over Na2SO4, is concentrated to dryness. The under vacuum distillation of the obtained residue affords 2.8 grams (93 percent of theoretical) of the title compound. B.p./0.2 mmHg 140--1420C. The corresponding hydrochloride prepared by treatment of the free base with HCI melts at 110--1110C.
Example 14 N-ethyl-2,3-dihydro-6-methoxy-2-methyl-4-benzofuranamine 3 grams of 2,3-dihydro-6-methoxy-2-methyl-4-benzofuranamine and 2.02 grams of triethylamine in 30 cc of anhydrous benzene are poured in a steel reaction vessel and added with 5 cc of ethyl bromide and trace amounts of potassium iodide.
The reaction vessel is sealed and heated in an oil-bath to 1000C for 15 tours.
At the end of this time the reaction mixture is allowed to cool and then filtered. The filtrate is concentrated to dryness and an oily residue is obtained which on distillation under reduced pressure yields 1.1 grams of the desired product. B.p./0.5 mmHg 135"C.
Example 15 N,N-diethyl-2,3-dihydro-6-methoxy-2-methyl-4-benzofuranamine The alkylation reaction is carried out exactly as in the preceding exa chloride cooled to 50C, a solution of 24.5 grams of phenacylsulfonyl chloride in 80 cc of methylene chloride is added. When the dripping is terminated the reaction mixture is warmed to room temperature and stirred for 5 hours. At the end of this time the solution is washed with water, dried over sodium sulfate and concentrated to dryness. Crystallization of the resulting thick oil from ethyl alcoholethyl ether gives 16 grams of the compound of the title which melts at 143--1450C.
Example 21 N-(2, 3-dihydro-6-methoxy-2-methyl-4-b enzofuranyl)urea 2.5 grams of 2,3-dihydro-6-methoxy-2-methyl-4-benzofuranamine are dissolved in 16 cc of 0.1N HC1 and upon glacial addition of 1.1 gram of sodium cyanate to the resulting solution a white crystalline solid precipitates. The reaction mixture is then heated in a water-bath and, after 90 minutes, cooled and filtered. By recrystallizing the obtained precipitate from ethyl alcohol 1.9 gram (61 percent of theoretical) of the desired product is obtained. M.p. 204w060C.
Example 22
(2,3-dihydro-6-methoxy-2-methyl-4-benzofuranyl)carbamic acid
phenylmethyl ester
0.65 grams of phenylmethylchlorocarbonate are dripped at 50C into a stirred mixture containing fi 0.7 grams of 2,3-dihydro-6-methoxy-2-methyl-4benzofuranamine hydrochloride, 5 cc of 2N NaOH'and 10 cc of chloroform. When the addition is terminated vigorous stirring is continued for one hour at the same temperature and for two hours at room temperature. Then the organic phase is separated, washed with water, dried over Na2SO4 and concentrated to dryness. The obtained residue crystallized twice from ethyl ether-petroleum ether yields 0.9 grams (88 percent of theoretical) of (2,3-dihydro-6-methoxy-2-methyl-4benzofuranyl)carbamic acid phenylmethyl ester which melts at 82-830C.
Example 23
N-(2, 3-dihydro-6-methoxy-2-methyl-4-benzofuranyl)
N-methylpropanamide
The reaction is carried out as in example 10 by dripping propionyl chloride into a benzene solution of 2,3-dihydro-6-methoxy-N-2-dimethyl-4benzofuranamine and triethylamine. Recovery of the crude end product is achieved by cooling the reaction mixture, previously refluxed for two hours, separating the obtained precipitate which, ground with benzene and filtered, is then discarded and finally concentrating the benzene filtrate to dryness. Distillation under reduced pressure of the resulting residue affords 2 grams (90 percent of theoretical) of pure compound. B.p./0.4 mmHg 14--142"C.
Example 24 (2,3-dihydro-4-methoxy-2-methyl-6-benzofuranyl)carbamic acid ethyl ester
A solution of 4.5 cc of SOCI2 in 10 cc of anhydrous benzene is added drop by drop to 6.5 grams of 2,3-dihydro-4-methoxy-2-methyl-6-benzofurancarboxylic acid, prepared in example 2, suspended in 65 cc of anhydrous benzene and a few drops of
N,N-dimethylformamide. The reaction mixture is gradually heated up to 70--800 C and stirred at the same temperature for 4 hours. Then the solvent is evaporated and the obtained thick oil is dissolved in 65 cc of acetone. 3.9 grams of NaN3 in 15 cc of water are added into the resulting solution cooled to about 5"C and stirring is continued at the same temperature for an additional hour.
At the end of this time the reaction mixture is poured into 400 cc of icy water and extracted twice with 100 cc of ethyl ether. The organic phase is evaporated and the residue redissolved in 150 cc of ethyl ether and dried over Na2SO4 is concentrated to a small volume. The solid which precipitates upon addition of petroleum ether is dissolved in 60 cc of anhydrous xylene and heated under stirring up to 1200C. After 30 minutes at this temperature, 10 cc of anhydrous ethanol are added and the mixture is heated in an oil-bath to 1300C for 3 hours. At the end of this time the reaction mixture is concentrated to dryness and the resulting residue is distilled under reduced pressure wherein the fraction which at 0.4 mm Hg boils at 17Q80"C is collected: crystallization from ethyl ether/petroleum ether of the solidified distillate gives 5 grams (78 percent of theoretical) of the compound of the title. M.p. 93--94"C.
Example 25 2,3-dihydro-4-methoxy-N,2-dimethyl-6-benzofuranamine The compound of the title is prepared according to the procedures described in example 11 but starting from (2,3-dihydro-4-methoxy-2-methyl-6benzofuranyl)carbamic acid ethyl ester. B.p./0.2 mmHg 1300C. Yield 94%.
The corresponding hydrochloride, crystallized from ethanol/ethyl ether melts at 157--1580C.
Example 26
2,3-dihydro-6-hydroxy-N,2-dimethyl-4-benzofuranamine
5 cc of 48% HBr are added to a solution of 5 grams of 2,3-dihydro-6-methoxy
N,2-dimethyl-4-benzofuranamine hydrochloride in 20 cc of acetic acid and the resulting mixture is refluxed for 16 hours. At the end of this 'time the solvent is evaporated off and the residue, taken up with sodium bicarbonate, is thoroughly extracted with ether. Evaporation of this organic phase, previously dried over
Na2SO4, gives a crude residue which crystallized from ethyl ether-petroleum ether yields 3 grams of the desired end product. Yield 77 percent of theoretical. M.p.
126--128"C.
Example 27 6-acetoxy-2,3-dihydro-N,2-dimethyl-4-benzofuranamine hydrochloride
1.7 grams of the compound prepared in the foregoing example are added to 20 cc of ethanol containing 0.8 grams of HBr. Upon evaporation a tarry residue is obtained which is carefully dried in vacuo over P2O5. Then it is dissolved in 20 cc of CF3COOH and 1.4 grams of CH4COBr are gradually added into the resulting solution. After stirring for one hour a few drops of water are added and the reaction mixture is concentrated to dryness under reduced pressure by gently heating. The obtained residue is dissolved in a small amount of cold water and the solution made basic by addition of NaHCO3 is thoroughly extracted with ethyl ether.
Evaporation of the ether phase and purification of the resulting residue by column chromatography using CHCI3+ 1% acetone as the eluting system affords 6 acetoxy-2,3-dihydro-N,2-dimethyl-4-benzofuranamine whose hydrochloride, crystallized from ethanol/ether, melts at 159--1600C (Yield 57% of theoretical).
Other 2-methyl-4,6-disubstituted-2,3-dihydrobenzofurans (i.e. compounds of formula I in which R is hydrogen) which can be prepared by the procedures exemplified above are those in which R2 is methoxy and R1 is dimethylamino, Nacetyl-N-methylamino, isopropylamino, phenylsulphonylamino, ptolylsulphonylamino or cyano, in which R, is N-acetyl-N-methylamino and R2 is hydroxy, or in which R1 is methoxy and R2 is isopropylamino.
The starting materials (2- and 4-)allyl-3-hydroxy-5-methoxybenzoic acid may be prepared by reacting methyl 3-hydroxy-5-methoxybenzoate with allyl bromide to prepare ethyl 3-allyloxy-5-methylbenzoate (b.p. 128--300C/0.4 mm Hg). This compound may be subjected to allylic rearrangement by refluxing in N,Ndimethylaniline under nitrogen for about 6 hours. After cooling, evaporation of the solvent, washing the residue with cold dilute HCI and extraction with aqueous 20%
NaOH, the 4-allyl and 2-allyl starting materials may be separated by fractional crystallisation on acidification.
A pharmaceutical composition of this invention comprises a compound of the invention in association with a physiologically acceptable excipient.
WHAT WE CLAIM IS:
1. A compound of the formula
wherein R is hydrogen or methyl, one of R, and R3 is hydroxy, C,~4alkoxy or C34all:anoyloxy and the other is cyano, carboxy, carbo(C,~4)alkoxy, carbamoyl or -NR3R4, in which R3 and R4 are the same or different and are each hydrogen, C,~4alkyl, C24alkanoyl, carbo(C,~4)alkoxy, carbobenzyloxy, carbamoyl, mono- or di-(C,~4)alkylamino-(C, 4)alkyl, benzenesulphonyl, toluenesulphonyl,
**WARNING** end of DESC field may overlap start of CLMS **.
Claims (10)
- **WARNING** start of CLMS field may overlap end of DESC **.Example 25 2,3-dihydro-4-methoxy-N,2-dimethyl-6-benzofuranamine The compound of the title is prepared according to the procedures described in example 11 but starting from (2,3-dihydro-4-methoxy-2-methyl-6benzofuranyl)carbamic acid ethyl ester. B.p./0.2 mmHg 1300C. Yield 94%.The corresponding hydrochloride, crystallized from ethanol/ethyl ether melts at 157--1580C.Example 26 2,3-dihydro-6-hydroxy-N,2-dimethyl-4-benzofuranamine5 cc of 48% HBr are added to a solution of 5 grams of 2,3-dihydro-6-methoxy N,2-dimethyl-4-benzofuranamine hydrochloride in 20 cc of acetic acid and the resulting mixture is refluxed for 16 hours. At the end of this 'time the solvent is evaporated off and the residue, taken up with sodium bicarbonate, is thoroughly extracted with ether. Evaporation of this organic phase, previously dried over Na2SO4, gives a crude residue which crystallized from ethyl ether-petroleum ether yields 3 grams of the desired end product. Yield 77 percent of theoretical. M.p.126--128"C.Example 27 6-acetoxy-2,3-dihydro-N,2-dimethyl-4-benzofuranamine hydrochloride 1.7 grams of the compound prepared in the foregoing example are added to 20 cc of ethanol containing 0.8 grams of HBr. Upon evaporation a tarry residue is obtained which is carefully dried in vacuo over P2O5. Then it is dissolved in 20 cc of CF3COOH and 1.4 grams of CH4COBr are gradually added into the resulting solution. After stirring for one hour a few drops of water are added and the reaction mixture is concentrated to dryness under reduced pressure by gently heating. The obtained residue is dissolved in a small amount of cold water and the solution made basic by addition of NaHCO3 is thoroughly extracted with ethyl ether.Evaporation of the ether phase and purification of the resulting residue by column chromatography using CHCI3+ 1% acetone as the eluting system affords 6 acetoxy-2,3-dihydro-N,2-dimethyl-4-benzofuranamine whose hydrochloride, crystallized from ethanol/ether, melts at 159--1600C (Yield 57% of theoretical).Other 2-methyl-4,6-disubstituted-2,3-dihydrobenzofurans (i.e. compounds of formula I in which R is hydrogen) which can be prepared by the procedures exemplified above are those in which R2 is methoxy and R1 is dimethylamino, Nacetyl-N-methylamino, isopropylamino, phenylsulphonylamino, ptolylsulphonylamino or cyano, in which R, is N-acetyl-N-methylamino and R2 is hydroxy, or in which R1 is methoxy and R2 is isopropylamino.The starting materials (2- and 4-)allyl-3-hydroxy-5-methoxybenzoic acid may be prepared by reacting methyl 3-hydroxy-5-methoxybenzoate with allyl bromide to prepare ethyl 3-allyloxy-5-methylbenzoate (b.p. 128--300C/0.4 mm Hg). This compound may be subjected to allylic rearrangement by refluxing in N,Ndimethylaniline under nitrogen for about 6 hours. After cooling, evaporation of the solvent, washing the residue with cold dilute HCI and extraction with aqueous 20% NaOH, the 4-allyl and 2-allyl starting materials may be separated by fractional crystallisation on acidification.A pharmaceutical composition of this invention comprises a compound of the invention in association with a physiologically acceptable excipient.WHAT WE CLAIM IS: 1. A compound of the formulawherein R is hydrogen or methyl, one of R, and R3 is hydroxy, C,~4alkoxy or C34all:anoyloxy and the other is cyano, carboxy, carbo(C,~4)alkoxy, carbamoyl or -NR3R4, in which R3 and R4 are the same or different and are each hydrogen, C,~4alkyl, C24alkanoyl, carbo(C,~4)alkoxy, carbobenzyloxy, carbamoyl, mono- or di-(C,~4)alkylamino-(C, 4)alkyl, benzenesulphonyl, toluenesulphonyl,C,~4)alkylsulphonyl or phenacylsulphonyl; or a pharmaceutically acceptable acid addition salt thereof.
- 2. A compound as claimed in claim 1 wherein one of R1 and R2 is hydroxy, C,~4alkoxy or C2~4alkanoyloxy and the other is -NR3R4 in which R3 and R4 are the same or different and are each hydrogen or C14alkyl; or a pharmaceutically acceptable acid addition salt thereof.
- 3. A compound as claimed in claim 1 wherein R is hydrogen, one of R, and R2 is a C,~4alkoxy group and the other is -NR3R4 wherein R3 and R4 are the same or different and are each hydrogen or C,~4alkyl; or a pharmaceutically acceptable acid addition salt thereof.
- 4. 2,3-Dihydro-6-methoxy-N,2-dimethyl-4-benzofuranamine.
- 5. A process for preparing a compound or salt as claimed in claim 1, which comprises subjecting a compound of the formulawherein R is as defined in claim 1 and the -CH2-CH=CH-R group is at the 2or 4-position of the phenyl ring, to thermal or acid-induced cyclisation, thereby forming the product wherein one of R, and R2 is methoxy and the other is carboxy or carbomethoxy, and, if desired, converting that product to another compound or salt as claimed in claim 1 by a method known per se.
- 6. A process according to claim 5 in which the cyclisation is carried out at a temperature of from 200 to 2800 C.
- 7. A process according to claim 5 in which the cyclisation is carried out in the presence of a mixture of acetic acid and hydrobromic acid.
- 8. A process for preparing a compound or salt as claimed in claim 1 substantially as described in any of the Examples.
- 9. A compound or salt as claimed in claim 1 when prepared by a process according to any of claims 5 to 8.
- 10. A pharmaceutical composition comprising a compound as claimed in any of claims 1 to 4 and 9 in association with a physiologically acceptable excipient.
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB14242/77A GB1574959A (en) | 1977-04-05 | 1977-04-05 | Benzofuran derivatives |
| AU33856/78A AU513200B2 (en) | 1977-04-05 | 1978-03-06 | 2, 4, 6-Trisubstituted-2, 3-dihydro-benzofuran derivatives |
| ZA00781345A ZA781345B (en) | 1977-04-05 | 1978-03-07 | New 2,46-trisubstituted-2,3-dihydro-benzofuran derivatives |
| IL54244A IL54244A0 (en) | 1977-04-05 | 1978-03-09 | New 2,4,6-trisubstituted-2,3-dihydro-benzofuran derivatives |
| FI780908A FI780908A7 (en) | 1977-04-05 | 1978-03-22 | NYA 2 4 6-TRISUBSTITUERADE 2 3-DIHYDROBENZOFURANDE |
| IT21749/78A IT1158677B (en) | 1977-04-05 | 1978-03-30 | NEW 2,3, HYDRO-BENZOFURANIC DERIVATIVES 2, 4, 6-TRISOSTITUTI |
| DE19782813895 DE2813895A1 (en) | 1977-04-05 | 1978-03-31 | NEW 2,4,6-TRISUBSTITUTED 2,3-DIHYDROBENZOFURANE DERIVATIVES |
| NO781127A NO781127L (en) | 1977-04-05 | 1978-03-31 | NEW 2,4,6-TRISUBSTITUATED-2,3-DIHYDRO-BENZOFURAN DERIVATIVES, AND PROCEDURES FOR THEIR PREPARATION |
| LU79368A LU79368A1 (en) | 1977-04-05 | 1978-04-03 | PROCESS FOR PREPARATION OF NEW DERIVATIVES OF 2,3-DIHYDRO-BENZOFURANNE TRISUBSTITUES IN POSITIONS 2,4,6 |
| DK147878A DK147878A (en) | 1977-04-05 | 1978-04-04 | PROCEDURE FOR THE PREPARATION OF 2,4,6-TRISUBSTITUTED 2,3-DIHYDROBENZOFURAND DERIVATIVES |
| SE7803804A SE7803804L (en) | 1977-04-05 | 1978-04-04 | BENZOFURAN DERIVATIVES |
| JP3889178A JPS53124257A (en) | 1977-04-05 | 1978-04-04 | Novel 2*4*66triisubstitutedd2*33dihydroo benzofuran derivative and method for its production |
| FR7810107A FR2386539A1 (en) | 1977-04-05 | 1978-04-05 | 2,3-DIHYDRO BENZOFURAN 2,4,6-TRISUBSTITUES, THEIR PREPARATION PROCESS AND THEIR USE AS ANTI-INFLAMMATORY, ANALGESIC AND ANTIPYRETICS |
| NL7803610A NL7803610A (en) | 1977-04-05 | 1978-04-05 | 2,4,6-TRI-SUBSTITUTED 2,3-DIHYDROBENZOFURANS. |
| BE186578A BE865706A (en) | 1977-04-05 | 1978-04-05 | NEW 2,3-DIHYDRO-BENZOFURAN DERIVATIVES AND THEIR PREPARATION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB14242/77A GB1574959A (en) | 1977-04-05 | 1977-04-05 | Benzofuran derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1574959A true GB1574959A (en) | 1980-09-10 |
Family
ID=10037611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB14242/77A Expired GB1574959A (en) | 1977-04-05 | 1977-04-05 | Benzofuran derivatives |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JPS53124257A (en) |
| AU (1) | AU513200B2 (en) |
| BE (1) | BE865706A (en) |
| DE (1) | DE2813895A1 (en) |
| DK (1) | DK147878A (en) |
| FI (1) | FI780908A7 (en) |
| FR (1) | FR2386539A1 (en) |
| GB (1) | GB1574959A (en) |
| IL (1) | IL54244A0 (en) |
| IT (1) | IT1158677B (en) |
| LU (1) | LU79368A1 (en) |
| NL (1) | NL7803610A (en) |
| NO (1) | NO781127L (en) |
| SE (1) | SE7803804L (en) |
| ZA (1) | ZA781345B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2064290B1 (en) | 2006-10-27 | 2013-10-09 | Life Technologies Corporation | Fluorogenic ph sensitive dyes and their method of use |
-
1977
- 1977-04-05 GB GB14242/77A patent/GB1574959A/en not_active Expired
-
1978
- 1978-03-06 AU AU33856/78A patent/AU513200B2/en not_active Expired
- 1978-03-07 ZA ZA00781345A patent/ZA781345B/en unknown
- 1978-03-09 IL IL54244A patent/IL54244A0/en unknown
- 1978-03-22 FI FI780908A patent/FI780908A7/en not_active Application Discontinuation
- 1978-03-30 IT IT21749/78A patent/IT1158677B/en active
- 1978-03-31 DE DE19782813895 patent/DE2813895A1/en not_active Withdrawn
- 1978-03-31 NO NO781127A patent/NO781127L/en unknown
- 1978-04-03 LU LU79368A patent/LU79368A1/en unknown
- 1978-04-04 SE SE7803804A patent/SE7803804L/en unknown
- 1978-04-04 DK DK147878A patent/DK147878A/en not_active Application Discontinuation
- 1978-04-04 JP JP3889178A patent/JPS53124257A/en active Pending
- 1978-04-05 BE BE186578A patent/BE865706A/en unknown
- 1978-04-05 NL NL7803610A patent/NL7803610A/en not_active Application Discontinuation
- 1978-04-05 FR FR7810107A patent/FR2386539A1/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| IT1158677B (en) | 1987-02-25 |
| ZA781345B (en) | 1979-02-28 |
| IL54244A0 (en) | 1978-06-15 |
| FR2386539B1 (en) | 1980-08-14 |
| AU513200B2 (en) | 1980-11-20 |
| DE2813895A1 (en) | 1978-10-19 |
| BE865706A (en) | 1978-10-05 |
| NO781127L (en) | 1978-10-06 |
| FI780908A7 (en) | 1978-10-06 |
| IT7821749A0 (en) | 1978-03-30 |
| AU3385678A (en) | 1979-09-13 |
| NL7803610A (en) | 1978-10-09 |
| DK147878A (en) | 1978-10-06 |
| JPS53124257A (en) | 1978-10-30 |
| SE7803804L (en) | 1978-10-06 |
| FR2386539A1 (en) | 1978-11-03 |
| LU79368A1 (en) | 1978-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5708020A (en) | Arylalkyl(thio)amides | |
| EP0264586B1 (en) | Hydantoin derivatives for treating complications of diabetes | |
| CA1100959A (en) | Indolo (2,3-a) quinolizidines, preparation and therapeutic use | |
| EP0496238A1 (en) | Substituted benzoxazepines and benzothiazepines, process for their preparation and their use as medicaments | |
| US3652569A (en) | Ergonine ergoptine and the 1-methyl and 9 10-dihydro derivatives thereof | |
| US4143055A (en) | 2,4,6-trisubstituted-2,3-dihydro-benzofuran derivatives | |
| KR920002295B1 (en) | Method for preparing prolidinone derivative | |
| US4877884A (en) | 4-benzyloxy-3-pyrrolin-2-on-1-yl acetamide production | |
| EP0070531B1 (en) | Tetrahydronaphthoxazoles | |
| GB1574959A (en) | Benzofuran derivatives | |
| EP0198762B1 (en) | Dibenzo[b,e]oxepine-acetic-acid derivatives, their preparation, and pharmaceutical preparations containing them | |
| US4247697A (en) | 3-Phenoxy morphinans and their derivatives | |
| US4194044A (en) | Process for preparing 3-phenoxy morphinans | |
| US3055888A (en) | 2-alkylmercapto-9-[2'-(n-alkylpiperidyl-2" and pyrrolidyl-2")-ethylidene-1']-thiaxanthenes | |
| US4507308A (en) | Analgesically or anti-inflammatory effective 4-quinolyl anthranilic acid derivatives | |
| CA1266659A (en) | Nitroapovincaminic acid derivatives, pharmaceutical compositions containing them and process for preparing same | |
| US4506078A (en) | 7-Nitroindoles | |
| US3956391A (en) | Amino substituted tetrahydropleiadenes | |
| US3879462A (en) | Amino substituted tetrahydropleiadenes | |
| US4201870A (en) | Process for the preparation of 2-(3-benzoylphenyl)-propionic acid | |
| US3557108A (en) | Phthalazino-phthalazinediones and process for their manufacture | |
| KR930002279B1 (en) | Method for preparing benzo [a] phenazine derivative | |
| US4010161A (en) | Piperazinoethyl-N-(2,3-dimethyl-5-oxo-1-phenyl-3Δ-pyrazolin-4-yl)carbamates | |
| US4376860A (en) | Pyridyl ketone | |
| US3949091A (en) | 8-Substituted dibenzobicyclo[3.2.1]octadienes for treating depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CSNS | Application of which complete specification have been accepted and published, but patent is not sealed |